Bethpage Parent, Inc. acquires ENZO BIOCHEM INC (2025)

Deal facts

Buyer: Bethpage Parent, Inc.
Target: ENZO BIOCHEM INC
Deal value: Not disclosed
Announced: 20 August 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

20 Aug 2025CompletedClosed
Bethpage Parent, Inc. completes acquisition of ENZO BIOCHEM INC
Introductory Note This Current Report on Form 8-K is being filed in connection with the completion of the previously announced Merger (as defined below) pursuant to the Agreement and Plan of Merger, dated as of June 23, 2025 (the “Merger Agreement”), by and among Enzo Biochem, Inc., a New York corporation (the “Company”), Bethpage Parent, Inc., a Delaware corporation (“Parent”), and Bethpage Merge
Source

OpinionExit Mode editorial

We see a clear signal in the completion of the acquisition of ENZO BIOCHEM INC by Bethpage Parent, Inc. on 20 August 2025. This transaction, valued at 0.7 million USD, represents a definitive shift from public markets to private ownership within the US healthcare sector. The all-cash consideration structure removes the volatility often associated with stock-based deals, offering immediate certainty for shareholders. For the SME founder watching from across the Atlantic, this underscores a recurring theme: public markets are not the only destination for growth, nor the only path to liquidity.

The decision to take a listed entity private often stems from a desire to escape the short-term pressures of quarterly reporting cycles. In the healthcare sector, where R&D timelines are long and regulatory hurdles are high, this freedom can be vital. While this specific deal involved a US target and buyer, the mechanics of a going-private transaction carry universal lessons. A cash deal of this nature typically requires strict adherence to change-of-control covenants and may trigger regulatory reviews depending on the competitive landscape. Although the value is modest, the structural shift is significant. It demonstrates that buyers are willing to deploy capital to secure control and streamline operations without the distraction of public scrutiny.

We must note that while the deal is completed, the underlying dynamics remain relevant for any founder considering a similar exit. The absence of an earn-out or contingent consideration in this cash-only structure suggests the buyer saw clear value in the asset as it stood. This contrasts with many deals where future performance dictates final payment. For the SME founder, this highlights the importance of presenting a business that can stand on its own merits without relying on future projections to justify the price. It is a reminder that clean, auditable financials and a clear strategic fit often outweigh speculative growth stories in a private transaction.

Our view is that you should audit your current shareholder agreement this week to identify any change-of-control triggers that could complicate a future sale. Do not wait until you are in talks to understand how a buyout might affect your debt covenants or employee share schemes. Knowing these constraints now allows you to structure your business for a smoother exit, whether the buyer is a public company or a private group looking to take a firm private.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More going private deals More from Bethpage Parent, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history